These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 34189716)

  • 1. Diabetes, Heart Failure and Beyond: Elucidating the Cardioprotective Mechanisms of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors.
    Ojha U; Reyes L; Eyenga F; Oumbe D; Watkowska J; Saint-Jacques H
    Am J Cardiovasc Drugs; 2022 Jan; 22(1):35-46. PubMed ID: 34189716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidemiology of Heart Failure and the Discovery of the Cardioprotective Effects of SGLT2 Inhibitors.
    Butler J; Rich J
    JACC Heart Fail; 2024 Jun; 12(6S):S1-S3. PubMed ID: 38839134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigating the place of sodium-glucose cotransporter-2 inhibitors and dual sodium-glucose cotransporter-1 and dual sodium-glucose cotransporter-2 inhibitors in heart failure therapy: a systematic review of the literature.
    McKenzie T; Hale GM; Miner A; Colón Colón J; Evins G; Wade J
    Heart Fail Rev; 2024 Mar; 29(2):549-558. PubMed ID: 38300379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sodium-glucose linked transporter 2 inhibitors in liver cirrhosis: Beyond their antidiabetic use.
    Siafarikas C; Kapelios CJ; Papatheodoridi M; Vlachogiannakos J; Tentolouris N; Papatheodoridis G
    Liver Int; 2024 Apr; 44(4):884-893. PubMed ID: 38293770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SGLT2 inhibitors in hypertension: Role beyond diabetes and heart failure.
    Gupta R; Maitz T; Egeler D; Mehta A; Nyaeme M; Hajra A; Goel A; Sreenivasan J; Patel N; Aronow WS
    Trends Cardiovasc Med; 2023 Nov; 33(8):479-486. PubMed ID: 35597430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early SGLT2 Inhibitors in Acute Heart Failure: Safe Diuretic-Sparing Strategy.
    Costanzo MR; Januzzi JL
    J Am Coll Cardiol; 2024 Apr; 83(14):1307-1309. PubMed ID: 38569759
    [No Abstract]   [Full Text] [Related]  

  • 7. The Cardioprotective and Anticancer Effects of SGLT2 Inhibitors:
    Dabour MS; George MY; Daniel MR; Blaes AH; Zordoky BN
    JACC CardioOncol; 2024 Apr; 6(2):159-182. PubMed ID: 38774006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time to SGLT2 Inhibitors Initiation in Patients With Heart Failure.
    Moon J; Udell JA; Chong A; Fang J; Austin PC; Ko DT; Stukel TA; Atzema CL; Booth GL; Tu K; Naimark DMJ; Jackevicius CA
    J Am Heart Assoc; 2024 Apr; 13(8):e032296. PubMed ID: 38563368
    [No Abstract]   [Full Text] [Related]  

  • 9. Sweet relationship between SGLT2 inhibition and heart failure.
    Nabeshima Y; Tanaka A; Node K
    Int J Cardiol; 2024 Sep; 410():132223. PubMed ID: 38830544
    [No Abstract]   [Full Text] [Related]  

  • 10. Time-varying effects of sodium-glucose cotransporter-2 inhibitors in patients with heart failure: An updated meta-analysis.
    Zou X; Shi Q; Li S
    J Evid Based Med; 2024 Mar; 17(1):13-16. PubMed ID: 38465841
    [No Abstract]   [Full Text] [Related]  

  • 11. As Good as it Gets: SGLT2 Inhibitors in Cardiac Amyloidosis.
    Pinney SP; Costanzo MR
    J Am Coll Cardiol; 2024 Jun; 83(24):2423-2425. PubMed ID: 38866446
    [No Abstract]   [Full Text] [Related]  

  • 12. Sodium-glucose cotransporter-2 inhibition in a CKD patient with severe heart failure treated by high-dose diuretics and peritoneal ultrafiltration: lesson for the clinical nephrologist.
    Borrelli S; Garofalo C; Liberti ME; Ruotolo C; Capozzi F; Yavorskiy P; De Nicola L
    J Nephrol; 2024 Jan; 37(1):199-201. PubMed ID: 37707693
    [No Abstract]   [Full Text] [Related]  

  • 13. Summary and Panel Discussion.
    Butler J; Rich J; Pessah-Pollack R; Anderson JE
    JACC Heart Fail; 2024 Jun; 12(6S):S10-S11. PubMed ID: 38839135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are Sodium-Glucose Cotransporter-2 Inhibitors the Cherry on Top of Cardio-Oncology Care?
    Gongora CA; Zhang L; Mattei JL; Ruiz-Mori E; Gonzalez-Robledo G; Slipczuk L; Lara J; Cossio-Aranda JE; Badimon J
    Cardiovasc Drugs Ther; 2024 Jul; ():. PubMed ID: 38958827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Research progress on the effects of SGLT2 inhibitors on multiple metabolic disorders in metabolic syndrome.
    Xu C; Cai X; Qiu X; Zhao L
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2024 Jun; ():1-9. PubMed ID: 38899358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SGLT2 Inhibitors and Iron: More Than Meets the Eye.
    Docherty KF
    JACC Heart Fail; 2023 Nov; 11(11):1623-1625. PubMed ID: 37737759
    [No Abstract]   [Full Text] [Related]  

  • 17. Narrative Review of Immunomodulatory and Anti-inflammatory Effects of Sodium-Glucose Cotransporter 2 Inhibitors: Unveiling Novel Therapeutic Frontiers.
    Lee SA; Riella LV
    Kidney Int Rep; 2024 Jun; 9(6):1601-1613. PubMed ID: 38899203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SGLT2 inhibition for outcomes: Is this the panacea?
    Ferdinand KC; Arora N
    Am Heart J Plus; 2022 Sep; 21():100159. PubMed ID: 38559750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postpartum cardiomyopathy with congestive heart failure: A case report.
    Jayte M; Mohamud A; Dubad F
    SAGE Open Med Case Rep; 2024; 12():2050313X241263761. PubMed ID: 38911174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Response To: Sodium-Glucose Cotransporter 2 Inhibitors and Major COVID-19 Outcomes: Promising Mechanisms, Conflicting Data, and Intriguing Clinical Decisions.
    Bossi AC; Forloni F; Colombelli PL
    Diabetes Ther; 2020 Dec; 11(12):3007-3009. PubMed ID: 33052537
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.